- Home
- GNK vs URGN Comparison
GNK vs URGN Comparison
Compare GNK & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNK
- URGN
- Stock Information
- Founded
- GNK 2004
- URGN 2004
- Country
- GNK United States
- URGN United States
- Employees
- GNK N/A
- URGN N/A
- Industry
- GNK Marine Transportation
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- GNK Consumer Discretionary
- URGN Health Care
- Exchange
- GNK Nasdaq
- URGN Nasdaq
- Market Cap
- GNK 803.8M
- URGN 830.4M
- IPO Year
- GNK 2005
- URGN 2017
- Fundamental
- Price
- GNK $16.12
- URGN $16.67
- Analyst Decision
- GNK Buy
- URGN Strong Buy
- Analyst Count
- GNK 2
- URGN 8
- Target Price
- GNK $18.00
- URGN $28.50
- AVG Volume (30 Days)
- GNK 693.2K
- URGN 1.2M
- Earning Date
- GNK 11-05-2025
- URGN 11-05-2025
- Dividend Yield
- GNK 9.38%
- URGN N/A
- EPS Growth
- GNK 0.36
- URGN N/A
- EPS
- GNK 0.36
- URGN N/A
- Revenue
- GNK $350,742,000.00
- URGN $94,238,000.00
- Revenue This Year
- GNK N/A
- URGN $39.63
- Revenue Next Year
- GNK $9.76
- URGN $111.49
- P/E Ratio
- GNK $43.80
- URGN N/A
- Revenue Growth
- GNK N/A
- URGN 10.85
- 52 Week Low
- GNK $11.20
- URGN $3.42
- 52 Week High
- GNK $19.60
- URGN $21.71
- Technical
- Relative Strength Index (RSI)
- GNK 36.93
- URGN 42.09
- Support Level
- GNK $16.89
- URGN $15.86
- Resistance Level
- GNK $17.24
- URGN $17.43
- Average True Range (ATR)
- GNK 0.53
- URGN 1.05
- MACD
- GNK -0.32
- URGN -0.16
- Stochastic Oscillator
- GNK 13.65
- URGN 19.33
About GNK Genco Shipping & Trading Limited New (Marshall Islands)
Genco Shipping & Trading Ltd is an international shipping company specializing in the transportation of iron ore, coal, grain, steel products and other drybulk cargoes. It is involved in the ocean transportation of drybulk cargoes. The company operates in one segment, with two reportable segment: Major and Minor bulk fleet. It generates revenue through time charter agreements, spot market voyage charters, pool agreements and spot market-related time charters. oyage revenues also include the sale of bunkers consumed during short-term time charters pursuant to the terms of the time charter agreement.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.